binding kinetics
Recently Published Documents


TOTAL DOCUMENTS

999
(FIVE YEARS 177)

H-INDEX

64
(FIVE YEARS 9)

2022 ◽  
Vol 3 (1) ◽  
pp. 101078
Author(s):  
Charles S. Lay ◽  
Daniel A. Thomas ◽  
John P. Evans ◽  
Emma J. Jones ◽  
Kelly M. Gatfield ◽  
...  

2022 ◽  
pp. 131408
Author(s):  
Young Hun Seo ◽  
Taemin Kim ◽  
Cuong Khac Phu Truong ◽  
Hyun Seung No ◽  
Jong-In Hong ◽  
...  

The Analyst ◽  
2022 ◽  
Author(s):  
Ji Yoon Lee ◽  
Joon Won Park

DNA methylation plays key roles in various areas, such as gene expression, regulation, epigenetics, and cancers. Since 5-methylcytosine (5mC) is commonly present in methylated DNA, characterizing the binding kinetics and...


2021 ◽  
Author(s):  
Carlos Moreno-Yruela ◽  
Christian Adam Olsen

Histone deacetylases (HDACs) 1-3 regulate chromatin structure and gene expression. These three enzymes are targets for cancer chemotherapy and are studied for the treatment of immune disorders and neurodegeneration, but there is a lack of selective pharmacological tool compounds to unravel their individual roles. Potent inhibitors of HDACs 1-3 often display slow-binding kinetics, which causes a delay in inhibitor-enzyme equilibration and may affect assay readout. Here, we compare the potency and selectivity of slow-binding inhibitors measured by discontinuous and continuous assays. We find that entinostat, a clinical candidate, inhibits HDACs 1-3 by a two-step, slow-binding mechanism with lower potencies than previously reported. In addition, we show that RGFP966, commercialized as HDAC3-selective probe, is a slow-binding inhibitor with inhibitor constants of 57 nM, 31 nM, and 13 nM against HDACs 1-3, respectively. These data highlight a need for thorough kinetic investigation in the development of selective HDAC probes.


F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 1236
Author(s):  
Magdalena Ługowska ◽  
Marcin Pacholczyk

Background: Difficulties in translating the in vitro potency determined by cellular assays into in vivo efficacy in living organisms complicates the design and development of drugs. However,  the residence time of a drug in its molecular target is becoming a key parameter in the design and optimization of new drugs, as recent studies show that residence time can reliably predict drug efficacy in vivo. Experimental approaches to binding kinetics and target ligand complex solutions are currently available, but known bioinformatics databases do not usually report information about the ligand residence time in its molecular target. Methods: To extend existing databases we developed the Protein Data Bank (PDB) residence time database (PDBrt) which reports drug residence time. The database is implemented as an open access web-based tool. The front end uses Bootstrap with Hypertext Markup Language (HTML), jQuery for the interface and 3Dmol.js to visualize the complexes. The server-side code uses Python web application framework, Django Rest Framework and backend database PostgreSQL. Results: The PDBrt database is a free, non-commercial repository for 3D protein-ligand complex data, including the measured ligand residence time inside the binding pocket of the specific biological macromolecules as deposited in The Protein Data Bank. The PDBrt database contains information about both the protein and the ligand separately, as well as the protein-ligand complex, binding kinetics, and time of the ligand residence inside the protein binding site. Availability: https://pdbrt.polsl.pl


eLife ◽  
2021 ◽  
Vol 10 ◽  
Author(s):  
Jing Li ◽  
Jiabin Yan ◽  
Timothy A Springer

Integrin conformational ensembles contain two low-affinity states, bent-closed and extended-closed, and an active, high-affinity, extended-open state. It is widely thought that integrins must be activated before they bind ligand; however, one model holds that activation follows ligand binding. As ligand-binding kinetics are not only rate limiting for cell adhesion but also have important implications for the mechanism of activation, we measure them here for integrins α4β1 and α5β1 and show that the low-affinity states bind substantially faster than the high-affinity state. On and off-rates are similar for integrins on cell surfaces and as ectodomain fragments. Although the extended-open conformation's on-rate is ~20-fold slower, its off-rate is ~25,000-fold slower, resulting in a large affinity increase. The tighter ligand-binding pocket in the open state may slow its on-rate. Low affinity integrin states not only bind ligand more rapidly, but are also more populous on the cell surface than high affinity states. Thus, our results suggest that integrin binding to ligand may precede, rather than follow, activation by 'inside-out signaling'.


2021 ◽  
pp. 101505
Author(s):  
Andre Bazzone ◽  
Laura Tesmer ◽  
Derya Kurt ◽  
H. Ronald Kaback ◽  
Klaus Fendler ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document